ArticleFEMS microbiology letters2026
Characterization of antimicrobial peptide WAM-1 and its interactions with clinical isolates of Acinetobacter baumannii.
Article in FEMS microbiology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acinetobacter baumannii, a prominent nosocomial pathogen, commonly causes life-threatening disease in immunocompromised individuals with mortality rates approaching 35%. Known for its multidrug resistance, studies investigating antimicrobial peptides (AMPs) have proven promising. We have previously shown that the AMP WAM-1 exhibits potent bactericidal activity against A. baumannii, but its full therapeutic value and mechanism of action have not yet been elucidated. To evaluate the potential clinical relevance of WAM-1, we characterized its antibacterial effects, inhibition by lipopolysaccharide (LPS), and whether treatment with WAM-1 induced resistance in A. baumannii. Additionally, we explored WAM-1's mechanism of action by visualizing structural changes induced by treatment with WAM-1 and evaluating permeabilization of the bacterial outer membrane. The activity of WAM-1 was comparable to that of efficacious antibiotics and was not inhibited by the presence of exogenous LPS. Scanning electron microscopy showed evidence of membrane disruption, cellular content leakage, and cell lysis, indicating damage to the bacterial outer membrane, and depolarization of the membrane was observed. WAM-1 was found to induce resistance more slowly than tested antibiotics. Overall, our data indicates that WAM-1 may be a promising therapeutic option for A. baumannii infections and may act, at least in part, by damaging the outer membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.